0001630113 false 0001630113 2021-12-06 2021-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): December 6, 2021

 

BIOTRICITY INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40761   30-0983531
(State or Other Jurisdiction of Incorporation or Organization)  

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

275 Shoreline Drive, Suite 150
Redwood City, California 94065

(Address of Principal Executive Offices)

 

(650) 832-1626
(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

  Name of each exchange on which registered
Common Stock, par value $0.001 per share   BTCY   NASDAQ Capital Markets

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure

 

On December 6, 2021, Biotricity, Inc. (the “Company”) published on its website the 2021 letter to shareholders (the “Shareholder Letter”) describing recent milestones and goals for 2022.

 

A copy of the Shareholder Letter is furnished as Exhibits 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and in Item 9.01 of this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit99.1).

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits. The exhibit listed in the following Exhibit Index is furnished as part of this Current Report on Form 8-K:

 

Exhibit Number   Description
99.1   2021 Letter to Shareholders
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: December 7, 2021

 

  BIOTRICITY INC.
     
  By: /s/Waqaas Al-Siddiq
    Waqaas Al-Siddiq
    Chief Executive Officer

 

 

 

 

 

Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Dec 2024 to Dec 2024 Click Here for more Biotricity (QB) Charts.
Biotricity (QB) (USOTC:BTCY)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Biotricity (QB) Charts.